Neurim reports positive Piromelatine Phase II study data
According to the double-blind, randomised study data, Piromelatine 20/50mg four-week treatment demonstrated statistically significant and clinically meaningful improvements in key polysomnographic (PSG) parametres such as Wake After Sleep
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.